Brought to you by 
Incyte gets European rights to Ariad's Iclusig
11 May 2016
Executive Summary
In conjunction with its acquisition of the firm's European operations, Incyte Corp. licensed exclusive rights to Ariad Pharmaceuticals Inc.'s Iclusig (ponatinib). Incyte will develop and sell the leukemia treatment in the European Union and 22 other countries, including Switzerland, Norway, Turkey, Israel, and Russia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Incyte gets European rights to Ariad's Iclusig
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice